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The molecular chaperone Hsp90 is a hub of protein
homeostasis and regulatory circuitry. Hsp90 function
is regulated by posttranslational modifications
including acetylation in mammals; however, whether
this regulation is conserved remains unknown. In
fungi, Hsp90 governs the evolution of drug resis-
tance by stabilizing signal transducers. Here, we
establish that pharmacological inhibition of lysine
deacetylases (KDACs) blocks the emergence and
maintenance of Hsp90-dependent resistance to
the most widely deployed antifungals, the azoles, in
the human fungal pathogen Candida albicans
and the model yeast Saccharomyces cerevisiae.
S. cerevisiae Hsp90 is acetylated on lysine 27 and
270, and key KDACs for drug resistance are Hda1
and Rpd3. Compromising KDACs alters stability
and function of Hsp90 client proteins, including the
drug-resistance regulator calcineurin. Thus, we
establish acetylation as a mechanism of posttransla-
tional control of Hsp90 function in fungi, functional
redundancy between KDACs Hda1 and Rpd3, as
well as a mechanism governing fungal drug resis-
tance with broad therapeutic potential.INTRODUCTION
Hsp90 is an essential molecular chaperone that is conserved
among all eukaryotes. Hsp90 has a specialized role in regulating
the form and function of diverse client proteins by binding to
metastable regulators of cellular signaling and key components
of multiprotein complexes (Taipale et al., 2010; Trepel et al.,
2010). Hsp90 is constitutively expressed at much higher levels
than required to fulfill its normal functions, constituting a large
but highly specific protein-folding reservoir. As a consequence,
Hsp90modulates the relationship betweengenotype andpheno-
type by acting as a capacitor and potentiator for the storage and
release of genetic variation in response to environmental stress
(Jarosz and Lindquist, 2010). By governing the expression of878 Cell Reports 2, 878–888, October 25, 2012 ª2012 The Authorsphenotypic diversity in an environmentally contingent manner,
Hsp90 is poised to enable evolution (Jarosz et al., 2010).
In diverse fungal species, Hsp90 potentiates the evolution of
drug resistance by enabling the phenotypic effects of resistance
mutations (Cowen and Lindquist, 2005). Fungal pathogens are
a leading cause of human mortality worldwide, especially in
immunocompromised individuals. Chief among the opportu-
nistic invaders is the fungal pathogen Candida albicans, which
is a leading causal agent of mycotic death (Pfaller and Diekema,
2010). Hsp90 enables the emergence of resistance to the most
widely deployed antifungal drugs in the clinic, the azoles. The
azoles inhibit lanosterol demethylase, encoded by ERG11,
causing a block in the production of ergosterol and the accumu-
lation of a toxic sterol produced by Erg3 (Ostrosky-Zeichner
et al., 2010; Shapiro et al., 2011). Genetic or pharmacological
inhibition of Hsp90 blocks the emergence of azole resistance
and abrogates resistance that had already been acquired by
diverse mutations in both C. albicans and the model yeast
Saccharomyces cerevisiae (Cowen et al., 2006; Cowen and Lind-
quist, 2005). For example, loss of function of Erg3 in the ergos-
terol biosynthetic pathway blocks the accumulation of toxic
sterols and confers resistance that is contingent upon Hsp90-
mediated stress responses (Cowen, 2008). Hsp90’s role in azole
resistance depends on the mode of selection. A more gradual
selection regimen favors the evolution of Hsp90-independent
resistance where drug-induced stress is bypassed by upregula-
tion of multidrug transporters that efflux drugs from the cell
(Cowen and Lindquist, 2005).
Hsp90 orchestrates cellular circuitry required for responses to
drug-induced stress and can be targeted for the treatment of
life-threatening fungal infections. The Hsp90 client protein calci-
neurin, a signal transducer and sensor of cellular stress, is a key
mediator of Hsp90-dependent azole resistance in C. albicans
and S. cerevisiae (Cowen and Lindquist, 2005; Singh et al.,
2009). By chaperoning calcineurin, Hsp90 regulates membrane
stress responses that are crucial for cells to survive azole expo-
sure, thereby enabling the phenotypic consequences of new
resistance mutations. Targeting Hsp90 has broad therapeutic
potential because Hsp90 inhibitors that are well tolerated in
humans are synergistic with azoles againstC. albicans in ameta-
zoan model of fungal disease (Cowen et al., 2009), and in a rat
catheter model of biofilm infection (Robbins et al., 2011). Hsp90
governs not only the cellular circuitry required for drug resistance
but also that required for pathogenesis. Hsp90 orchestrates
temperature-dependent C. albicans morphogenesis, a key viru-
lence trait (Gow et al., 2012; Shapiro et al., 2011), and depletion
ofC. albicansHsp90 results in clearance of a disseminated infec-
tion in a mouse model (Shapiro et al., 2009). Hence, changes in
a global regulator of signaling can potentiate evolution with
profound implications for abrogating drug resistance and treating
infectious disease.
Despite the fundamental importance of Hsp90 as a hub of
protein homeostasis and regulatory circuitry, and its profound
impact on diverse facets of biology, disease, and evolution, an
understanding of how Hsp90 function is regulated remains in
its infancy. Recently, it has become appreciated that Hsp90 is
subject to complex regulation by posttranslational modification.
In both mammals and yeast, Hsp90 function is regulated by
phosphorylation of several serine, threonine, and tyrosine resi-
dues (Taipale et al., 2010; Trepel et al., 2010). Phosphorylation
of S. cerevisiae Hsp90 on tyrosine 24 by the Swe1 kinase and
on threonine 22 by protein kinase CK2 is important for Hsp90’s
ability to interact with and stabilize several cochaperones and
client proteins (Mollapour et al., 2010, 2011). Moreover, in
mammalian cells the class IIb histone deacetylase 6 (HDAC6)
complex regulates Hsp90 deacetylation, which is required for
Hsp90 interaction with select cochaperones and for stabilization
of several Hsp90 client proteins (Bali et al., 2005; Kovacs et al.,
2005; Scroggins et al., 2007). Given that many key targets of
histone deacetylases are now appreciated to be nonhistone
proteins (Choudhary et al., 2009), we conform with the more
appropriate lysine deacetylase (KDAC) terminology. Although
Hsp90 lysine acetylation is well established in mammalian
systems, whether this mechanism of posttranslational control
is conserved in other species remains unknown.
TargetingHsp90provides a powerful strategy for the treatment
of life-threatening fungal infections; however, there are thera-
peutic challenges given that compromise of host Hsp90 function
has deleterious effects in the context of acute systemic fungal
infections (Cowen et al., 2009), motivating the present study to
identify novel regulators of Hsp90 function and fungal drug
resistance. Given that Hsp90 function is regulated by acetylation
inmammals, we investigatedwhether this regulatorymechanism
is conserved in fungi and if it influences fungal drug resistance.
Our results implicate acetylation as a mechanism of posttransla-
tional control of Hsp90 in fungi, establish functional redundancy
between Hda1 and Rpd3, identify lysine 27 and lysine 270 as
functionally important acetylated residues on Hsp90, and estab-
lish a mechanism of fungal drug resistance with broad implica-
tions for treatment of life-threatening fungal disease.
RESULTS
KDAC Inhibition Blocks the Emergence and
Maintenance of Hsp90-Dependent Azole Resistance
Given that KDACs regulate Hsp90 function in mammalian cells
(Aoyagi and Archer, 2005) and that Hsp90 potentiates the emer-
gence and maintenance of fungal drug resistance (Cowen and
Lindquist, 2005), we hypothesized that KDACs govern fungal
drug resistance by regulating Hsp90 function in fungi. First, we
tested if pharmacological inhibition of KDAC function with tri-Cchostatin A blocked the emergence of azole resistance in
C. albicans. To select for resistant mutants, we used a rapid
selection regimen and plated 13 105 cells onto richmediumcon-
taining a high concentration of the azolemiconazole. Cells under-
went several doublings before growth was arrested, producing
small abortive colonies (Figure 1A). Large colonies were also
recovered that upon further retesting displayed elevated resis-
tance to azoles (data not shown). Including a concentration of
trichostatin A in the medium that had no impact on growth on
its own completely blocked the emergence of colonies in the pre-
sence of miconazole (Figure 1A), as was the case with the Hsp90
inhibitor radicicol (Figure 1A; Cowen and Lindquist, 2005). Thus,
the rapid emergence of azole resistance inC. albicans is critically
dependent upon Hsp90 and KDAC function.
Next, we assessed whether KDACs enabled the maintenance
of drug resistance that had already evolved inC. albicans clinical
isolates (CaCis) collected from a single patient infected with HIV
who was undergoing fluconazole therapy (White, 1997). We
monitored resistance to the azole fluconazole in the presence
or absence of pharmacological inhibitors of KDAC or Hsp90
function by minimum inhibitory concentration (MIC) assays. Inhi-
bition of Hsp90 with geldanamycin or KDACs with trichostatin A
markedly reduced resistance of all clinical isolates, especially for
clinical isolates recovered earlier during treatment (Figure 1B).
Azole resistance in this series evolved from a state of Hsp90
dependence toward independence accompanying the accumu-
lation of additional mutations in the azole target ERG11 and over-
expression of the drug pump Cdr1 (Cowen and Lindquist, 2005;
White, 1997). The transition to KDAC independence perfectly
recapitulates that observed with Hsp90 independence, suggest-
ing functional relationships between these cellular regulators.
Given that clinical isolates often harbormultiplemechanismsof
resistance, we next tested the impact of KDAC inhibition on azole
resistance of laboratory-derived mutants to evaluate the depen-
dence of specific resistance mechanisms on KDAC function.
Furthermore, to determine whether KDACs have a conserved
impact on drug resistance in other fungi, we turned to the genet-
ically tractable model yeast S. cerevisiae. Pharmacological inhi-
bition of KDACs with trichostatin A abrogated azole resistance
of C. albicans and S. cerevisiae erg3 loss-of-function mutants,
concordantwith the impact ofHsp90 inhibition (Figure 1C;Cowen
et al., 2006;CowenandLindquist, 2005; LaFayette et al., 2010). In
contrast, KDAC inhibition did not affect S. cerevisiae azole resis-
tance that had been acquired by an activating mutation in the
transcription factor Pdr1 that results in overexpression of the
multidrug transporter Pdr5 (Figure 1C), consistent with a robust
azole-resistance phenotype despite Hsp90 inhibition (Cowen
and Lindquist, 2005). Taken together, these results demonstrate
that KDAC inhibition affects azole resistance in a manner that
phenocopies Hsp90 inhibition, supporting the model that com-
promising KDAC function leads to impaired Hsp90 function,
thereby blocking stress responses critical for azole resistance.
Compromising KDAC Function Does Not Decrease
the Expression of Hsp90 or Key Drug-Resistance
Determinants
Given that a predominant function of KDACs is to deacetylate
lysines in core histones and thereby regulate gene expressionell Reports 2, 878–888, October 25, 2012 ª2012 The Authors 879
Figure 1. Trichostatin A Blocks the Emer-
gence and Maintenance of Drug Resistance
in C. albicans and S. cerevisiae
(A) A total of 13 105 cells of a wild-typeC. albicans
strain was plated onto YPD with no drug (),
800 nM of the azole miconazole (ML), 1 mM of the
Hsp90 inhibitor radicicol (RAD), 6 mg/ml of the
KDAC inhibitor trichostatin A (TSA), or a combina-
tion of azole and inhibitor, as indicated.
(B) Fluconazole (FL) resistance of C. albicans
clinical isolates is abrogated when KDACs are
inhibited. MIC assays were conducted in YPD
with no inhibitor (), with the Hsp90 inhibitor
geldanamycin (GdA, 5 mM), or with TSA (6 mg/ml).
C. albicans clinical isolates (CaCis) are ordered
sequentially with those recovered early in treat-
ment at the top. Data are quantitatively displayed
with color using TreeView (see bar).
(C) TSA specifically reduces FL resistance of
C. albicans and S. cerevisiae Hsp90-dependent
azole-resistant mutants. MIC assays were con-
ducted in YPDwith no inhibitor (), with GdA (1 mM
for C. albicans, 5 mM for S. cerevisiae), or with TSA
(6 mg/ml). Growth and analysis are as in (B).
PDR5\ represents a S. cerevisiae strain that
acquired FL resistance by upregulation of the drug
efflux pump Pdr5. erg3 represents a S. cerevisiae
strain that acquired FL resistance due to a loss-of-
function mutation in ERG3.
See also Table S1.(Shahbazian and Grunstein, 2007), we tested if compromising
KDAC function led to reduction of HSP90 levels. Treatment of
C. albicans with trichostatin A did not reduce HSP90 transcript
levels as measured by quantitative RT-PCR but rather led to a
small increase (p = 0.0011, t test; Figure 2A). Similarly, in
S. cerevisiae, trichostatin A did not reduce transcript levels of
either HSC82 or HSP82, the two genes encoding Hsp90: there
was no effect on HSP82 and only a very small increase of
HSC82 (p = 0.0101; Figure 2A). Western analysis for both
species confirmed that trichostatin A did not affect Hsp90
protein levels relative to a tubulin-loading control (Figure 2B).
Thus, pharmacological KDAC inhibition does not reduce
Hsp90 transcript or protein levels.
Our findings suggest that the relevant effects of trichostatin A
on azole resistance are not due to compromised gene expres-
sion because it had no impact on resistance that is dependent
on the overexpression of drug transporters (Figure 1C), nor did
it compromise expression of HSP90. Given that one study
demonstrated that trichostatin A blocks azole-induced upregu-
lation of resistance determinants in C. albicans (Smith and
Edlind, 2002), we measured transcript levels of the same resis-
tance determinants, including key multidrug transporters and880 Cell Reports 2, 878–888, October 25, 2012 ª2012 The Authorsthe azole target ERG11. In C. albicans,
trichostatin A did not impair basal expres-
sion or the fluconazole induction of the
multidrug transporters CDR1, CDR2, or
MDR1, or of the azole target ERG11; for
CDR2 and ERG11 there was no effect of
trichostatin A in the presence of flucona-zole, whereas for CDR1 and MDR1, trichostatin A led to an
increase in fluconazole-dependent induction of transcript levels
(p < 0.01, ANOVA, Bonferroni’s multiple comparison test; Fig-
ure 2C). Similarly, in S. cerevisiae, trichostatin A did not reduce
the basal expression, or the fluconazole induction, of the multi-
drug transporter PDR5 or the azole target ERG11 (p > 0.05;
Figure 2C). Thus, KDAC inhibition does not block the expression
of known resistance determinants but rather phenocopies
Hsp90 inhibition and reduces drug resistance, consistent with
compromised chaperone function.
TheKDACsHDA1 andRPD3Regulate Hsp90-Dependent
Azole Resistance in S. cerevisiae
To genetically confirm the pharmacological effects of trichostatin
A on erg3-mediated resistance and to determine which KDACs
were the key targets of trichostatin A for azole resistance, we
exploited the genetic tractability of S. cerevisiae. Based on
homology with the class IIb HDAC6 complex inmammalian cells,
we predicted that Hda1was a key KDAC for azole resistance and
that deletion ofHDA1 from an erg3mutant would abrogate azole
resistance, as with trichostatin A. However, deletion of HDA1
had no impact on azole resistance of an erg3mutant (Figure 3A).
Figure 2. Trichostatin A Does Not Decrease
the Expression of Hsp90 or Key Drug-Resis-
tance Determinants
(A) Treatment of C. albicans or S. cerevisiae with
trichostatin A (TSA) does not reduce Hsp90 gene
expression. Strains were grown in rich medium
to log phase without () or with TSA. Transcript
levels of gene(s) encoding Hsp90 were measured
by quantitative RT-PCR and normalized to GPD1
(C. albicans) or ACT1 (S. cerevisiae). Levels are
expressed relative to the untreated sample, which
is set to 1. Data are mean ± SD for triplicates.
(B) Treatment of S. cerevisiae or C. albicans with
TSA does not alter Hsp90 protein levels. Cultures
were grown as in (A). Total protein was resolved by
SDS-PAGE, and blots were hybridized with
a-Hsp90 or a-tubulin.
(C) TSA does not block the expression of
azole-resistance determinants. Transcript levels
of C. albicans or S. cerevisiae erg3 mutants were
measured by quantitative RT-PCR after growth
to log phase with no treatment, TSA, fluconazole
(FL), or the combination of TSA and FL. Transcript
levels are normalized as in (A).
See also Table S2.Deletion of other catalytic subunits of KDAC complexes
including RPD3, HOS1, HOS2, or HOS3 in an erg3 mutant also
did not abrogate azole resistance (Figures 3A and S1). However,
deletion of both HDA1 and RPD3 in an erg3 mutant reduced
fluconazole resistance back to wild-type levels, similar to the
impact of trichostatin A (Figures 1C and 3A). Notably, this effect
was specific for the combined deletion of RPD3 with HDA1
because deletion of other KDAC complexes in an erg3Dhda1D
mutant had no impact on azole susceptibility (Figure S1). These
findings suggest functional redundancy between Hda1 and
Rpd3 in the regulation of Hsp90-dependent azole resistance.
To determine if these KDACs specifically regulate azole resis-
tance in general or if their effects are specific to Hsp90-depen-
dent resistance mechanisms, as with trichostatin A, we deleted
HDA1 and RPD3 in a strain that overexpresses the drug pump
Pdr5 due to an activating mutation in the transcription factor
Pdr1. Deletion of HDA1 or RPD3 individually or in combination
did not alter azole resistance caused by drug pump overexpres-
sion (Figure 3B). Therefore, Hda1 and Rpd3 are not global
regulators of azole resistance but rather have a specialized role
in enabling Hsp90-dependent drug resistance, consistent with
the model that they influence resistance by modulating Hsp90
function.
Hsp90 Is Acetylated in S. cerevisiae, and the KDACs
Hda1 and Rpd3 Regulate Hsp90 Function
If deletion of HDA1 and RPD3 compromises Hsp90 function,
then thesemutants should be hypersensitive to Hsp90 inhibition.
To test this, we measured susceptibility of the wild-type strainCell Reports 2, 878–888,and KDAC mutants to the pharmacolog-
ical Hsp90 inhibitor geldanamycin. As
predicted, deletion of both HDA1 and
RPD3 increased sensitivity to geldana-mycin relative to individual gene deletions (Figure 4A). Western
analysis confirmed that the hypersensitivity was not due to
reduced Hsp90 protein levels relative to a tubulin-loading control
(Figure 4A). Thus, Hda1 and Rpd3 likely regulate Hsp90 function
at a posttranslational level.
To determine if Hsp90 is acetylated in yeast, we performed
immunoprecipitation assays coupled to western analysis. Immu-
noprecipitation of 63His-Hsp82 from all strains harboring the
tagged protein successfully pulled down Hsp90 (Figure 4B,
top-left panel). When the same immunoprecipitated samples
were probed with an antibody specific for acetylated-lysine
residues, bands were detected that corresponded to 90 kDa
(Figure 4B, middle-left panel). Notably, deletion of HDA1 and
RPD3 did not intensify the acetylation signal relative to a
wild-type strain or the individual KDAC deletion mutants. Recip-
rocally, protein extracts were immunoprecipitated using an
acetylated-lysine antibody coupled to protein A agarose. When
immunoprecipitated samples were probed with an Hsp90
antibody via western analysis, Hsp90 was pulled down approx-
imately equally among all strains (Figure 4B, right panel). This
demonstrates Hsp90 acetylation in fungi and suggests that
Hsp90 is acetylated on numerous lysine residues. Our results
suggest that Hda1 and Rpd3 may only regulate deacetylation
of one or a few of these residues, leading to compromised
Hsp90 chaperone function.
To identify the acetylated Hsp90 residues in the hda1Drpd3D
mutant, we turned to mass spectrometry. Hsp90 was immuno-
precipitated from a wild-type strain and an hda1Drpd3Dmutant.
After SDS-PAGE separation, bands corresponding to 90 kDaOctober 25, 2012 ª2012 The Authors 881
Figure 3. Deletion of RPD3 and HDA1, Encoding Catalytic Subunits
of Distinct KDAC Complexes, Decreases Azole Resistance of
Hsp90-Dependent Resistant Mutants in S. cerevisiae
(A) To identify the key targets of trichostatin A (TSA) that influence fluconazole
(FL) resistance, we tested the impact of deletion of KDACs individually
and in combination in an erg3 mutant in an FL MIC assay. The multiple
erg3Dhda1Drpd3D strains shown are independent meiotic progeny with the
confirmed genotype. Assays are performed as in Figure 1. See also Figure S1.
(B) Deletion of both HDA1 and RPD3 has no effect on azole resistance caused
by drug pump overexpression. Growth is as in (A) and analysis as in Figure 1.were excised and subjected to liquid chromatography-mass
spectrometry to identify posttranslational modifications. Lysine
27 (K27) on Hsp90 was identified as acetylated in two biological
hda1Drpd3D replicates and was not identified as acetylated in
either of the two wild-type biological replicates (Figure 4C).
This residue is located in the N-terminal nucleotide-binding
domain, corresponding to a region regulated by phosphorylation
in S. cerevisiae (Mollapour et al., 2010, 2011). This K27 was
the only residue identified as acetylated in both hda1Drpd3D
replicates and in neither wild-type replicate, suggesting that
modification of this residue might influence Hsp90 function.
To explore the impact of the K27 residue on Hsp90 function,
we constructed alleles of HSC82 with mutations of K27 to mimic
a constitutively acetylated state (glutamine) or a state that cannot
be acetylated (arginine). Vectors harboring a wild-type allele of
HSC82 or themutant alleleswere transformed into aS. cerevisiae
strain with the only native allele encoding Hsp90 expressed on
a counterselectable plasmid and that is resistant to azoles due882 Cell Reports 2, 878–888, October 25, 2012 ª2012 The Authorsto deletion of ERG3. Geldanamycin and fluconazole suscepti-
bility of strains in which the only allele encoding Hsp90 was
expressed from the vectors was assessed. We predicted
that mutating Hsp90 lysine residues that are important for its
function would confer increased geldanamycin and fluconazole
sensitivity in an erg3 background, as is observed with the
erg3Dhda1Drpd3D mutant (Figures 3A and 4A). However,
mutations in K27 alone did not alter susceptibility to geldana-
mycin (Figure 4D) or fluconazole (Figure S2). Hence, deacetyla-
tion of this residue cannot be solely responsible for the effects
of Hda1 and Rpd3 on Hsp90 function. In mammalian systems
lysine 294 is a key acetylated Hsp90 residue that regulates inter-
action with cochaperones and client proteins (Scroggins et al.,
2007). To determine if this residue is also acetylated in fungi,
we created point mutations of K270, the S. cerevisiae counter-
part to K294, to mimic acetylated and deacetylated states
individually as well as in combination with K27. Lysine to arginine
mutation of both K27 and K270 significantly reduced the amount
of Hsp90 immunoprecipitated using an acetylated-lysine anti-
body (Figure 4C), demonstrating two key residues on which
Hsp90 is acetylated in yeast. Functional characterization
revealed that mutating both of these residues to either glutamine
or arginine conferred hypersensitivity to geldanamycin com-
pared to a wild-type strain (p < 0.01, ANOVA, Bonferroni’s
multiple comparison test; Figure 4D), indicative of compromised
chaperone function. Notably, mutating K270 to arginine alone
caused geldanamycin hypersensitivity, which was further
enhanced upon mutation of K27. Mutation of K27 and K270
did not increase susceptibility to fluconazole (Figure S2), impli-
cating additional targets of Hda1 and Rpd3 in azole resistance.
Taken together, these results suggest that Hsp90 is acetylated
in yeast on K27 and K270 and that these residues have a
profound impact on Hsp90 function.
Compromised KDAC Function Blocks the Interaction
of Hsp90 with Its Client Protein Calcineurin, Thereby
Compromising Calcineurin Function
In order to assess whether trichostatin A abrogates Hsp90-
dependent azole resistance via impairment of Hsp90 client
protein function, we focused on the protein phosphatase
calcineurin. Upon calcineurin activation in response to calcium,
calcineurin dephosphorylates Crz1 to drive expression of genes
containing calcineurin-dependent response elements (CDREs)
in their promoters (Karababa et al., 2006; Stathopoulos and
Cyert, 1997). If trichostatin A compromises Hsp90 function,
then it should block calcium-induced calcineurin activation. To
test this hypothesis, we used reporters that contained
CDREs fused upstream of lacZ. As predicted, exposure of
S. cerevisiae or C. albicans to calcium chloride activated
calcineurin relative to the untreated control (p < 0.001, ANOVA,
Bonferroni’s multiple comparison test; Figure 5A). Treatment
with trichostatin A prior to and during calcium exposure blocked
calcium-induced calcineurin activation to a similar extent as gel-
danamycin in both species (p < 0.001; Figure 5A). Thus, KDAC
inhibition blocks calcineurin activation in both S. cerevisiae and
C. albicans.
Next, we assessed the physical interaction between Hsp90
and calcineurin, which is important for calcineurin stability and
Figure 4. Hsp90 Is Acetylated in
S. cerevisiae, and Compromising KDAC
Function Results in Hypersensitivity to
Further Hsp90 Inhibition
(A) Deletion of HDA1 and RPD3 in S. cerevisiae
causes hypersusceptibility to geldanamycin (GdA)
without altering Hsp90 protein levels. A titration
of GdA was generated, and growth was measured
as in Figure 1 (left panel). Total protein was
resolved by SDS-PAGE, and blots were hybridized
with a-Hsp90 or a-tubulin (right panels).
(B) Hsp90 is acetylated in S. cerevisiae. Immu-
noprecipitation of 63His-Hsp82 with NiNTA
agarose pulled down acetylated Hsp90 when
immunoprecipitated samples were hybridized
with a-Hsp90 or a-acetylated lysine (AcK).
Reciprocally, Hsp90 was immunoprecipitated
when protein extracts were incubated with
protein A agarose coupled to an AcK antibody. C,
a control lane where protein extracts were incu-
bated with protein A agarose in the absence of
AcK antibody; IB, immunoblot; IP, immunopre-
cipitate.
(C) Schematic of Hsp90 domain structure indi-
cating candidate acetylated lysine residues.
Mass spectrometry analysis identified a putative
acetylation site at K27 of S. cerevisiae Hsp82 in
an hda1Drpd3D mutant, indicated by an asterisk.
K270 has been identified in mammalian cells as
acetylated. Sequences containing the putative
acetylated lysines (bolded and underlined) are
shown below. Hsp90 was immunoprecipitated
with an AcK antibody as described in (B).
(D) K27 and K270 are functionally important
Hsp90 residues that are modified by acetylation.
Growth curves were conducted in YPD with or
without GdA over 48 hr, and the area under the
curve (AUC) was calculated. Data are mean ± SD
of quadruplicates.
See also Figure S2 and Table S3.activity (Imai and Yahara, 2000), in our S. cerevisiae KDAC
mutants and wild-type controls. Cna1 was immunoprecipitated
using anti-hemagglutinin (HA) agarose beads from all strains
containing the catalytic subunit of calcineurin, CNA1, HA tagged
(Figure 5B, top panel). Hsp90 copurified in all strains except
when both HDA1 and RPD3 were deleted, despite equivalent
levels of Hsp90 in all inputs (Figure 5B). Hence, deletion of
HDA1 and RPD3 blocks Hsp90 interaction with calcineurin,
thereby blocking calcineurin activation and providing a compel-
ling mechanism by which KDACs regulate Hsp90-dependent
azole resistance.
Compromised KDAC Function Leads to Altered Activity
and Stability of Numerous Hsp90 Client Proteins
Next, we addressed whether compromised KDAC function had
more global effects on Hsp90 client protein regulation. First,
we exploited reporter constructs that monitor the heat shock
response. In S. cerevisiae, Hsp90 exerts a repressive effect on
the transcription factor Hsf1, such that compromising Hsp90Cleads to upregulation of heat shock proteins and other targets
with heat shock elements (HSEs) in their promoters (Guo et al.,
2001). Comparable regulation is conserved in C. albicans
(Shapiro et al., 2009). For S. cerevisiae and C. albicans we
used reporters with HSEs driving lacZ expression andmonitored
b-galactosidase activity upon Hsp90 inhibition with geldanamy-
cin or KDAC inhibition with trichostatin A. Treatment with the
inhibitors led to a significant increase in lacZ expression relative
to the untreated control in both species (p < 0.001, ANOVA,
Bonferroni’s multiple comparison test; Figure 6A). We further
confirmed the pharmacological effects we observed in
S. cerevisiae genetically. When both HDA1 and RPD3 were
deleted, activation of the heat shock response was higher than
with a wild-type control or with the individual deletion mutants
at 30C (data not shown), and at the elevated temperature
of 42C (p < 0.001; Figure 6B). Thus, compromise of KDAC
function leads to activation of the heat shock response in both
S. cerevisiae and C. albicans, consistent with impaired Hsp90
function.ell Reports 2, 878–888, October 25, 2012 ª2012 The Authors 883
Figure 5. Inhibition of KDACs Impairs Calcineurin Activation and
Blocks the Interaction between Hsp90 and Calcineurin
(A) Geldanamycin (GdA) and trichostatin A (TSA) block calcium-induced
calcineurin activation. Log phase cultures of a S. cerevisiae strain containing
a 43CDRE-lacZ reporter or a C. albicans strain harboring a UTR2p-lacZ
construct were untreated (), treated with 200 mM CaCl2 (Ca), treated with
Ca and GdA, or treated with Ca and TSA. Data are mean ± SD from technical
triplicates and are representative of biological duplicates. *p < 0.001.
(B) Deletion ofHDA1 andRPD3 blocks the physical interaction between Hsp90
and calcineurin. Protein from S. cerevisiae strains harboring a HA-tagged
catalytic subunit of calcineurin (Cna1) was immunoprecipitated with anti-HA
agarose beads, resolved by SDS-PAGE, and blots were hybridized with a-HA
or a-Hsp90 antibodies. Experiment was quantified using ImageJ, and data are
mean ± SD of biological duplicates.We then examined the effect of KDAC inhibition on glucocor-
ticoid receptor (GR) activation. GR is a well-characterized Hsp90
client protein in mammalian cells, and reporters of its activity
have been used extensively in yeast (Pratt et al., 2004). We trans-
formed S. cerevisiae with a vector containing GR under a consti-
tutive promoter and with a plasmid containing a GR response
element driving lacZ expression. When Hsp90 is functional and
can assist in proper folding of GR, addition of the hormone
deoxycorticosterone leads to activation of GR such that it can
dimerize, translocate to the nucleus, and bind to response
elements. We observed that treatment of S. cerevisiae with de-
oxycorticosterone led to activation of the lacZ reporter relative
to the untreated control (p < 0.001, ANOVA, Bonferroni’s multiple
comparison test; Figure 6C), However, the KDAC inhibitor
trichostatin A blocked activation of GR to a similar extent as
inhibition of Hsp90 (p < 0.001; Figure 6C). Therefore, pharmaco-
logical KDAC inhibition impairs GR activation.
Next, we assessed the stability of the endogenous yeast client
protein kinase Ste11. We transformed S. cerevisiae with a884 Cell Reports 2, 878–888, October 25, 2012 ª2012 The Authorsconstruct containing a constitutively active variant of Ste11
that depends on Hsp90 for stability, Ste11DN, which is ex-
pressed under a galactose inducible promoter. Upon growth of
S. cerevisiae in galactose, Ste11 was detectable by western
analysis (Figure 6D). When cultures were grown in galactose
with geldanamycin or trichostatin A, Ste11 levels were reduced,
despite equivalent total protein as confirmed by an Hsp90-
loading control (Figure 6D). Thus, KDAC inhibition leads to desta-
bilization of the Hsp90 client kinase Ste11.
Finally, we examined the effect of KDAC inhibition on the v-Src
oncogenic tyrosine kinase, a well-established Hsp90 client
protein whose expression is toxic in yeast and whose stability
is highly dependent on Hsp90 (Nathan and Lindquist, 1995). A
strain of S. cerevisiae was transformed with a vector containing
v-Src under the control of a galactose-inducible promoter. Cells
were spotted onto glucose- or galactose-containing medium
with no inhibitor, with geldanamycin, or with trichostatin A.
v-Src-induced lethality was rescued upon Hsp90 inhibition,
but not KDAC inhibition (Figure 6E), suggesting that KDAC
function does not influence Hsp90’s ability to chaperone
v-Src. Overall, these findings suggest that KDAC regulation of
Hsp90 controls its ability to chaperone a distinct set of clients
(Figure 6), similar to Hsp90 regulation by phosphorylation
(Mollapour et al., 2010, 2011).
DISCUSSION
Our study provides one of the premier examples of regulation of
a nonhistone protein via acetylation in fungi, complementing the
emerging paradigm from mammalian cells that acetylation may
be as ubiquitous as phosphorylation (Choudhary et al., 2009).
Specifically, our results implicate acetylation as a mechanism
of posttranslational control of fungal Hsp90 function, establish-
ing a mechanism of drug resistance with broad therapeutic
potential. There is precedent for regulation of Hsp90 function
by deacetylation in mammalian cells, where the class IIb
HDAC6 complex deacetylates Hsp90, affecting its interaction
with cochaperones and regulation of client protein function
(Bali et al., 2005; Kovacs et al., 2005; Scroggins et al., 2007).
Our work implicates the class I KDAC, Rpd3, and the class II
KDAC, Hda1, as key regulators of Hsp90 deacetylation and
Hsp90-dependent azole resistance in S. cerevisiae. Convention-
ally, these KDACs act in distinct complexes to deacetylate
histones on different lysine residues (Rundlett et al., 1996), and
large-scale genomic analysis in yeast suggests that these
KDACs have largely nonoverlapping roles in protein deacetyla-
tion (Kaluarachchi Duffy et al., 2012). Recently, one study
demonstrated that Rpd3 and Hda1 may partially compensate
for each other in response to DNA damage by regulating stability
of the endonuclease Sae2 (Robert et al., 2011). Thus, our find-
ings provide a compelling example of cooperation between
traditionally disparate KDACs to regulate function of Hsp90,
a global regulator of protein homeostasis and cellular circuitry.
The emerging paradigm is that distinct aspects of Hsp90
function are modulated by a posttranslational code defined by
a multitude of regulators and target residues. We establish that
Hda1 and Rpd3 deacetylate K27 of Hsp90 despite not having
an impact on global Hsp90 acetylation levels, suggesting that
Figure 6. Inhibition of KDACs Impairs
Hsp90Client Protein Activation and Stability
(A) Geldanamycin (GdA) and trichostatin A (TSA)
induce the heat shock response in S. cerevisiae
and C. albicans. Log phase cultures of strains with
an HSE-lacZ reporter (S. cerevisiae) or HSP70p-
lacZ reporter (C. albicans) were untreated () or
treatedwithGdA or TSA. b-Galactosidase data are
mean ± SD for technical triplicates and are repre-
sentative of biological duplicates.
(B) Deletion of HDA1 and RPD3 enhances the
heat shock response. Log phase S. cerevisiae
harboring an HSE-lacZ reporter was grown at
42C for 3 hr.
(C) TSA blocks glucocorticoid receptor (GR)
maturation in S. cerevisiae. Wild-type S. cerevisiae
containing a GR expression plasmid and a GR
reporter plasmid with a GR response element
(GRE) driving lacZ expression was used. Matura-
tion of GR upon addition of deoxycorticosterone
(DOC, 10 mM) was assessed in the absence and
presence of GdA or TSA.
(D) TSA leads to destabilization of Ste11. Wild-
type S. cerevisiae was grown in SD with glucose
(glu) as a negative control or galactose (gal) to
induce 63His-Ste11 expression. Cultures grown
in galactose were grown without inhibitor () or
with GdA or TSA. Total protein was resolved by
SDS-PAGE, and blots were hybridized with a-His
or with a-Hsp90 as a loading control.
(E) TSA does not rescue v-Src-induced lethality in
S. cerevisiae. S. cerevisiae containing a vector
with v-Src under the control of a galactose-
inducible promoter was spotted in 5-fold dilutions
onto SD with 2% glucose or 2% galactose with no
drug (), GdA, or TSA. Images are representative
of biological duplicates.
*p < 0.001.additional lysine residues of Hsp90 are acetylated. Consistent
with this possibility, although human Hsp90 K294 regulates
aspects of Hsp90 function, human HSP90-a is thought to be
acetylated on at least 14 lysines and HSP90-b on a minimum
of 4 (Choudhary et al., 2009). Importantly, we demonstrate
that combined mutation of both the S. cerevisiae counterpart
of K294 (K270) and K27 reduces Hsp90 acetylation and com-
promises chaperone function. Notably, these mutations did not
reduce fluconazole susceptibility, suggesting that Hda1 and
Rpd3 deacetylate additional targets important for azole resis-
tance. The finding that mutation of K270 and K27 reduces global
Hsp90 acetylation, whereas deletion of HDA1 and RPD3 does
not, implicates additional KDACs in Hsp90 deacetylation. One
candidate KDAC is Hos2, based on the recent functional
connection identified between Hos2 and Hsp90 in C. albicans,
where Hos2 interacts genetically with Hsp90 under diverse
conditions (Diezmann et al., 2012). Combinatorial control of
acetylation status of a multitude of Hsp90 residues by diverse
KDACs may delineate a complex code to rapidly and reversibly
modulate function of a global cellular regulator.
Posttranslational modifications of Hsp90 define an emerging
code poised to have a myriad of effects on diverse facets of
biology, disease, and evolution. Examining Hsp90 regulation
by phosphorylation inS. cerevisiae has led to several key insightsCregarding biochemical regulation of this molecular chaperone.
Swe1 phosphorylates Hsp90 on tyrosine 24, and compromising
Swe1 function destabilizes client kinases and induces the heat
shock response; however, it has no impact on the GR (Mollapour
et al., 2010). Similarly, protein kinase CK2 phosphorylates Hsp90
on threonine 22, and phosphomimic mutants or mutants that
cannot be phosphorylated destabilize client kinases and alter
GR activity (Mollapour et al., 2011), suggesting that cycling
between phosphorylation states is critical for Hsp90 function.
S. cerevisiae Hsp90 is phosphorylated on at least 11 residues
(Mollapour et al., 2011), and there may be combinatorial control
based on their phosphorylation status. Our results suggest that
similar to phosphorylation, acetylation of Hsp90 on multiple resi-
dues controls its ability to chaperone distinct client proteins.
Compromising KDAC function blocks calcineurin activation,
destabilizes Ste11, activates the heat shock response, and
blocks GR activation, although it has no effect on v-Src-induced
toxicity. The precise mechanism by which these posttransla-
tional modifications alter Hsp90 function to influence select
clients remains elusive. It is likely that there is a dynamic and
complex code defined by phosphorylation, acetylation, and
perhaps other posttranslational modifications to dictate function
of Hsp90 and other cellular regulators. Because Hsp90 interacts
with 10% of the S. cerevisiae proteome (Zhao et al., 2005) andell Reports 2, 878–888, October 25, 2012 ª2012 The Authors 885
the C. albicans Hsp90 genetic interaction network reaffirms
Hsp90’s high degree of connectivity (Diezmann et al., 2012),
posttranslational control of Hsp90 function is likely to be funda-
mental for its capacity to modulate client proteins in a dynamic
and environmentally contingent manner.
Targeting Hsp90 has emerged as a powerful strategy for the
treatment of diverse diseases such as cancer, neurodegen-
erative disease, and infectious disease caused by protozoan
parasites and fungal pathogens, though there are therapeutic
challenges thatmight be overcomeby targetingHsp90 indirectly.
With fungal infections the Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin (17-AAG) transforms fluconazole from
ineffective to highly efficacious in a rat catheter model of biofilm
infection, where the infection and drug remain localized (Robbins
et al., 2011). However, in a murine model of disseminated
C. albicans infection, toxicity of systemic 17-AAG compromises
its therapeutic utility (Cowen et al., 2009), despite the fact that
genetic depletion of C. albicans Hsp90 clears the disseminated
infection (Shapiroet al., 2009).Our findings suggest that targeting
KDACs may provide a powerful alternative. KDACs are structur-
ally and functionally distinct from Hsp90 and are inhibited by
entirely different molecules, providing new opportunities for
drug development. Furthermore, the divergence of KDACs
between fungi and humans is greater than Hsp90. For example
the noncatalytic subunits of theHda1 complex are not conserved
in metazoans (Yang and Seto, 2008). Fungal-specific targets
provide critical avenues for exploitation tominimize host toxicity.
In support of this a fungal-specific Hos2 inhibitor has recently
been reported by Pfaller et al. (2009), though the biology under-
pinning its efficacy remains enigmatic. KDAC inhibitors have
emerged as important anticancer agents with benefits in clinical
trials as single or combination therapyagents (Boldenet al., 2006;
Marks et al., 2001; Xu et al., 2007). Furthermore, treatment
of patients with breast cancer with the KDAC inhibitor vorinostat
leads to enhanced Hsp90 acetylation and induction of Hsp70 in
tumor biopsies, suggesting functional Hsp90 inhibition in vivo
and validating this strategy to modulate Hsp90 via KDACs
(Ramaswamy et al., 2012). The challenge ahead for successfully
targeting KDACs in the treatment of infectious disease lies in
developing potent and specific inhibitors capable of discrimi-
nating between machineries of pathogen and host.
EXPERIMENTAL PROCEDURES
Strains and Culture Conditions
Strains are listed in Table S1, and their construction is described in the
Extended Experimental Procedures, as are culture conditions.
Plasmid Construction
Recombinant DNA procedures were performed according to standard proto-
cols. Primers used in this study are listed in Table S2. Plasmids used in this
study are listed in Table S3. Plasmid construction is described in the Extended
Experimental Procedures.
Selection of Azole-Resistant Mutants in C. albicans
For selection of azole resistance in C. albicans by a rapid, one-step regime,
CaLC75 was grown overnight in YPD at 30C. Cell counts were performed
with a hemacytometer, and 105 cells were plated on YPD agar to estimate
the number of viable colony-forming units, or YPD agar supplemented with
800 nM miconazole (Sigma-Aldrich), 1 mM of the Hsp90 inhibitor radicicol886 Cell Reports 2, 878–888, October 25, 2012 ª2012 The Authors(AG Scientific; R-1130), 6 mg/ml of the KDAC inhibitor trichostatin A (AG Scien-
tific; T-1052), or a combination of drugs as indicated. Each condition was per-
formed in duplicate. Plateswere photographed after 7 days at 30C in the dark.MIC Assays and Growth Curve Assays
Antifungal tolerance and resistance were determined in flat-bottom, 96-well
microtiter plates (Sarstedt) using a modified broth microdilution protocol
as described by LaFayette et al. (2010) and Singh et al. (2009). DMSO
(Sigma-Aldrich) was the solvent for the Hsp90 inhibitor geldanamycin
(ant-gl-5; Cedarlane) and trichostatin A; fluconazole (Sequoia Research Prod-
ucts) was dissolved in sterile ddH2O. MIC tests were set up in a total volume of
0.2 ml/well with 2-fold dilutions of fluconazole or geldanamycin. Plates were
incubated in the dark for 48 hr. Optical density (OD) was determined at
600 nm using a spectrophotometer (Molecular Devices) and corrected for
background from the corresponding medium. Each strain was tested in dupli-
cate on at least three occasions. MIC data were quantitatively displayed with
color using the program Java TreeView 1.1.1 (http://jtreeview.sourceforge.
net). For growth curves, cells were grown overnight in YPD, diluted to an
OD600 of 0.0625 with or without geldanamycin in 96-well plates, and grown
at 30Cwith continuous shaking (TECANGENios). OD595 was measured every
15 min. Data were analyzed in Microsoft Excel.b-Galactosidase Assays
All b-galactosidase assays were conducted as described previously by LaFay-
ette et al. (2010) and Singh et al. (2009). Detailed protocols are provided in the
Extended Experimental Procedures. Protein samples were diluted to the same
concentration, and b-galactosidase activity wasmeasured using the substrate
ONPG (O-nitrophenyl-b-D-galactopyranosidase; Sigma-Aldrich) as described
by Singh et al. (2009). b-Galactosidase activity is given in units of nanomoles
ONPG converted per minute per milligram of protein. Statistical significance
was evaluated using GraphPad Prism 4.0.v-Src Lethality Assay
Cultures were grown to log phase in synthetic-defined (SD) medium supple-
mented for auxotrophies and with 2% glucose. Cultures were washed and
resuspended in PBS. Five-fold dilutions (from 1 3 106 cells/ml) were spotted
onto freshly made agar medium using a spotter (Frogger; V&P Scientific). SD
agar plates were supplemented for auxotrophies and contained 2% glucose,
2% galactose, 10 mM geldanamycin, or 50 mg/ml trichostatin A, as indicated.
Plates were photographed after 4 days in the dark at 30C.Immunoblot Analysis and Immunoprecipitation
Total protein extracts were prepared as described previously (LaFayette et al.,
2010; Robbins et al., 2011). Immunoblotting was conducted as described
previously by Singh et al. (2009). Detailed immunoprecipitation and western
blotting protocols are provided in the Extended Experimental Procedures.Quantitative RT-PCR
S. cerevisiae and C. albicans were grown overnight in YPD with or without
trichostatin A (6 mg/ml), diluted to OD600 of 0.1, and grown for an additional
2 hr in duplicate. Fluconazole (16 mg/ml for S. cerevisiae or 8 mg/ml for
C. albicans) was then added to one of the duplicates, and cultures were
grown for 6 hr at 30C. RNA was isolated and PCR performed as described
(Cowen et al., 2009). See Extended Experimental Procedures for details on
primers used.Mass Spectrometry
Cells were grown overnight in SD with 2% glucose supplemented for auxotro-
phies at 30C. Cells were diluted to an OD600 of 0.2 in SD and grown to log
phase at 30C. Protein was harvested and immunoprecipitated using NiNTA
agarose, as above. Proteinwas separated by SDS-PAGE on an 8%acrylamide
gel and stained with Coomassie blue. Bands were excised for liquid chroma-
tography-mass spectrometry analysis at SickKids Mass Spectrometry facility.
See Extended Experimental Procedures for detailed protocols.
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